To the full analysis
Cencora stock: growth
CORCencora reported $337.4B in revenue for fiscal 2026, up 5% on the prior year, up 9.5% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
9%
per year from 2007 to 2026, per share 12.8%
Earnings (Annual rate)
11.1%
per year from 2007 to 2026, per share 15%
Free cash flow (Annual rate)
6.9%
per year from 2007 to 2026, per share 10.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 9.5% | 8.7% | 9.0% |
| Revenue per share | 10.9% | 9.7% | 12.8% |
| Earnings | 17.7% | 9.3% | 11.1% |
| Earnings per share | 19.2% | 10.4% | 15.0% |
| Free cash flow | 11.7% | 3.6% | 6.9% |
| Free cash flow per share | 13.2% | 4.6% | 10.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $66.07B | $469.17M | $1.09B |
| 2008 | $70.19B | $250.56M | $599.76M |
| 2009 | $71.76B | $503.4M | $637.93M |
| 2010 | $77.95B | $636.75M | $923.99M |
| 2011 | $80.22B | $706.62M | $999.99M |
| 2012 | $79.49B | $718.99M | $1.14B |
| 2013 | $87.96B | $433.71M | $585.68M |
| 2014 | $119.57B | $276.48M | $1.2B |
| 2015 | $135.96B | −$134.89M | $3.69B |
| 2016 | $146.85B | $1.43B | $2.71B |
| 2017 | $153.14B | $414.48M | $1.02B |
| 2018 | $167.94B | $1.66B | $1.07B |
| 2019 | $179.59B | $855.37M | $2.03B |
| 2020 | $189.89B | −$3.4B | $1.84B |
| 2021 | $213.99B | $1.54B | $2.23B |
| 2022 | $238.59B | $1.7B | $2.21B |
| 2023 | $262.17B | $1.75B | $3.45B |
| 2024 | $293.96B | $1.51B | $3B |
| 2025 | $321.33B | $1.55B | $3.21B |
| 2026 | $337.4B | $3.48B | $3.88B |
Revenue by segment
How Cencora, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Pharmaceutical Distribution89%
- International Healthcare Solutions9%
- Animal Health2%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Pharmaceutical Distribution | $182.17B | $229.72B | $259.97B | $285.29B | 88.8% |
| International Healthcare Solutions | $26.49B | $27.42B | $28.63B | $30.37B | 9.5% |
| Animal Health | $4.22B | $5.04B | $5.37B | $5.69B | 1.8% |
| Other | $25.71B | $0 | $0 | $0 | 0% |
| Total revenue | $238.59B | $262.17B | $293.96B | $321.33B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.